Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureEye (London), 2013-07, Vol.27 (7), p.787-794 [Peer Reviewed Journal]Copyright Nature Publishing Group Jul 2013 ;Copyright © 2013 Royal College of Ophthalmologists 2013 Royal College of Ophthalmologists ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/eye.2013.107 ;PMID: 23722722Full text available |
|
2 |
Material Type: Article
|
Ocular Drug Delivery: Present Innovations and Future ChallengesThe Journal of pharmacology and experimental therapeutics, 2019-09, Vol.370 (3), p.602 [Peer Reviewed Journal]Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. ;EISSN: 1521-0103 ;DOI: 10.1124/jpet.119.256933 ;PMID: 31072813Full text available |
|
3 |
Material Type: Article
|
Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle trackBritish journal of ophthalmology, 2012-08, Vol.96 (8), p.1084-1087 [Peer Reviewed Journal]2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;2015 INIST-CNRS ;Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2011-301016 ;PMID: 22368262 ;CODEN: BJOPALFull text available |
|
4 |
Material Type: Article
|
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degenerationCochrane database of systematic reviews, 2020-05, Vol.2020 (5), p.CD012208 [Peer Reviewed Journal]Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD012208.pub2 ;PMID: 32374423Full text available |
|
5 |
Material Type: Article
|
Intravitreal injections in the context of incarcerated patientsProbacja, 2023-11, Vol.4, p.337-347 [Peer Reviewed Journal]ISSN: 1689-6122 ;EISSN: 2719-311X ;DOI: 10.5604/01.3001.0054.1341Full text available |
|
6 |
Material Type: Article
|
Application of intravitreal aflibercept to treat bilateral exudative retinal detachment secondary to retinitis pigmentosa: Case report and review of literatureMedicine (Baltimore), 2023-12, Vol.102 (51), p.e36589-e36589 [Peer Reviewed Journal]Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. ;Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000036589 ;PMID: 38134121Full text available |
|
7 |
Material Type: Article
|
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsThe Lancet (British edition), 2022-02, Vol.399 (10326), p.729-740 [Peer Reviewed Journal]2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00010-1 ;PMID: 35085502Full text available |
|
8 |
Material Type: Article
|
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trialThe Lancet (British edition), 2019-10, Vol.394 (10208), p.1551-1559 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)31344-3 ;PMID: 31522845Full text available |
|
9 |
Material Type: Article
|
Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathyTheranostics, 2023-01, Vol.13 (7), p.2241-2255 [Peer Reviewed Journal]The author(s). ;The author(s) 2023 ;ISSN: 1838-7640 ;EISSN: 1838-7640 ;DOI: 10.7150/thno.78426 ;PMID: 37153730Full text available |
|
10 |
Material Type: Article
|
Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre studyGraefe's archive for clinical and experimental ophthalmology, 2023-08, Vol.261 (8), p.2421-2429 [Peer Reviewed Journal]The Author(s) 2023 ;ISSN: 0721-832X ;EISSN: 1435-702X ;DOI: 10.1007/s00417-023-05989-3Digital Resources/Online E-Resources |
|
11 |
Material Type: Article
|
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsThe Lancet (British edition), 2022-02, Vol.399 (10326), p.741-755 [Peer Reviewed Journal]2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00018-6 ;PMID: 35085503Full text available |
|
12 |
Material Type: Article
|
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX StudyAmerican journal of ophthalmology, 2019-01, Vol.197, p.156-167 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jan 2019 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.08.026 ;PMID: 30148987Full text available |
|
13 |
Material Type: Article
|
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBritish journal of ophthalmology, 2015-02, Vol.99 (2), p.220-226 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2014-305327 ;PMID: 25193672 ;CODEN: BJOPALFull text available |
|
14 |
Material Type: Article
|
Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal InjectionJournal of ocular pharmacology and therapeutics, 2023-04, Vol.39 (3), p.215-224 [Peer Reviewed Journal]Marjorie A. Peraza et al. 2023; Published by Mary Ann Liebert, Inc. ;Marjorie A. Peraza et al. 2023; Published by Mary Ann Liebert, Inc. 2023 Marjorie A. Peraza et al. ;ISSN: 1080-7683 ;EISSN: 1557-7732 ;DOI: 10.1089/jop.2022.0059 ;PMID: 36880872Full text available |
|
15 |
Material Type: Article
|
Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospitalIndian journal of ophthalmology, 2022-05, Vol.70 (5), p.1869-1869 [Peer Reviewed Journal]COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. ;2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Copyright: © 2022 Indian Journal of Ophthalmology 2022 ;ISSN: 0301-4738 ;EISSN: 1998-3689 ;DOI: 10.4103/ijo.IJO_1016_22 ;PMID: 35502117Full text available |
|
16 |
Material Type: Article
|
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaThe New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915Full text available |
|
17 |
Material Type: Article
|
Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot StudyAmerican journal of ophthalmology, 2015-07, Vol.160 (1), p.35-44.e1 [Peer Reviewed Journal]Elsevier Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jul 2015 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.04.021 ;PMID: 25896459 ;CODEN: AJOPAAFull text available |
|
18 |
Material Type: Article
|
Short-term efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-naïve exudate Age-related Macular Degeneration; A Multicenter StudyKorean journal of ophthalmology, 2023-10, Vol.37 (5), p.365-372 [Peer Reviewed Journal]2023 The Korean Ophthalmological Society 2023 ;ISSN: 1011-8942 ;EISSN: 2092-9382 ;DOI: 10.3341/kjo.2023.0009 ;PMID: 37562440Full text available |
|
19 |
Material Type: Article
|
Anti-vascular endothelial growth factor for neovascular age-related macular degenerationCochrane database of systematic reviews, 2014-08, Vol.8 (8), p.CD005139-CD005139 [Peer Reviewed Journal]Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2014 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD005139.pub3 ;PMID: 25170575Full text available |
|
20 |
Material Type: Article
|
Pharmacology of Corticosteroids for Diabetic Macular EdemaInvestigative ophthalmology & visual science, 2018-01, Vol.59 (1), p.1-12 [Peer Reviewed Journal]Copyright 2018 The Authors 2018 ;ISSN: 1552-5783 ;ISSN: 0146-0404 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.17-22259 ;PMID: 29297055Full text available |